PCRX

Pacira BioSciences

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

consensus rating "Strong Buy"

Revenue Beats Expectation

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About PCRX

Pacira Biosciences, Inc.

The industry leader in its commitment to non-opioid pain management and regenerative health solutions

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

02/03/2011

Exchange

NASDAQ Stock Exchange

Full-time Employees

788

Fiscal Year Ends

12-31

Website

www.pacira.com

Security Type

Common stock

Office address

5401 West Kennedy Boulevard, Suite 890, Tampa, Florida 33609

Business

Introduction

Founded in December 2006, Pacira BioSciences, Inc., has been conducting business related to EXPAREL since March 2007. The company is a specialty pharmaceutical company specializing in the development, commercialization and manufacture of pharmaceutical products based on the company's proprietary DepoFoam drug delivery technology, mainly used in hospitals and outpatient surgical centers. The company operates a reportable division. On October 28, 2011, the U.S. Food and Drug Administration (FDA) approved the Company's New Drug Application, or NDA, for the Company's lead product candidate, EXPAREL, a liposomal injection of bupivacaine, an amide-type local anesthetic suitable for infiltration into the surgical site to produce postoperative analgesia for up to 72 hours. The Company believes that EXPAREL addresses a significant unmet medical need for long-acting non-opioid postoperative analgesics, simplifying postoperative pain management and reducing opioid consumption, resulting in improved patient outcomes and improved hospital economics. The Company has developed an in-house sales force fully committed to commercializing EXPAREL, which the Company commercialized in April 2012. In addition, following the pilot program, effective October 1, 2013, the Company appointed CrossLink BioScience, LLC or CrossLink as the exclusive third-party distributor for a period of five years to promote and sell EXPAREL for orthopedic and spinal surgery in the United States, with the exception of certain geographic regions and accounts, which may be changed and adjusted according to the mutual agreement.

Company Financials

EPS

PCRX has released its 2024 Q4 earnings. EPS was reported at 0.91, versus the expected 0.83, beating expectations. The chart below visualizes how PCRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PCRX has released its 2024 Q4 earnings report, with revenue of 187.25M, reflecting a YoY change of 3.32%, and net profit of 16.04M, showing a YoY change of -35.50%. The Sankey diagram below clearly presents PCRX’s revenue sources and cost distribution.